Amgen has handed back the rights to two investigational heart failure programmes to Cytokinetics after one of the drugs failed to demonstrate impressive results in a phase III study.
Amgen, Cytokinetics, and Servier announced the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the second and final planned interim analysis ...